Loading stock data…
$3.63+0.03 (+0.83%)
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Prelude Therapeutics Incorporated in the Healthcare sector is trading at $3.63 with a market capitalization of $318M. Wall Street consensus targets $9.20 (5 analysts), implying a +153.4% move over the next 12 months. The stock is currently 47% below its 52-week high of $6.83, remaining 8.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.70M↑ | $4.58M↓ | $5.64M↓ | $6.50M | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.45M↓ | -$14.18M↑ | -$17.35M↑ | -$20.42M↑ | -$32.19M |
| Net Income | -$13.92M↓ | -$10.38M↑ | -$16.46M↑ | -$19.73M↑ | -$31.23M |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatm...